SCHEMBL1750376

SCHEMBL1750376

CC(N)(Cc1ccc(Br)cc1)C(=O)O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BLM P54132 2/20 0.71
MEN1 O00255 3/20 0.60
KMT2A Q03164 3/20 0.60
ALDH1A1 P00352 3/20 0.60
KDM4E B2RXH2 2/20 0.60
CYP1A2 P05177 2/20 0.60
POLB P06746 2/20 0.60
CYP3A4 P08684 2/20 0.60
MAPT P10636 2/20 0.60
HPGD P15428 2/20 0.60
ALOX15 P16050 2/20 0.60
HSD17B10 Q99714 2/20 0.60
TDP1 Q9NUW8 2/20 0.60
USP2 O75604 1/20 0.60
EGFR P00533 1/20 0.60
FYN P06241 1/20 0.60
GAA P10253 1/20 0.60
APEX1 P27695 1/20 0.60
ADRA1A P35348 1/20 0.60
PTGS2 P35354 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12530276 1.00 BLM (0.71) BLMMEN1KMT2AALDH1A1KDM4E
Bromide SCHEMBL8066241 0.98 BLM (0.69) BLMMEN1KMT2AALDH1A1KDM4E
Bromide SCHEMBL8066242 0.98 BLM (0.69) BLMMEN1KMT2AALDH1A1KDM4E
Metyrosine SCHEMBL50398 0.83 BLM (1.00) BLMMEN1KMT2AALDH1A1KDM4E
SCHEMBL6717498 0.83 BLM (0.73) BLMMEN1KMT2AALDH1A1KDM4E
Metyrosine SCHEMBL162280 0.83 BLM (1.00) BLMMEN1KMT2AALDH1A1KDM4E
Hydrochloric Acid SCHEMBL11335298 0.83 BLM (0.73) BLMMEN1KMT2AALDH1A1KDM4E
Racemetyrosine SCHEMBL61871 0.83 BLM (1.00) BLMMEN1KMT2AALDH1A1KDM4E
SCHEMBL6717499 0.83 BLM (0.73) BLMMEN1KMT2AALDH1A1KDM4E
SCHEMBL15218062 0.83 BLM (0.73) BLMMEN1KMT2AALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2542537-B1 NOVEL COMPOUNDS FOR MODULATION OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (ROR GAMMA, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASE PHENEX PHARMACEUTICALS AG (DE) 2014-05-21 EP disclosed
US-7968748-B2 Process for resolving racemic mixtures and a diastereoisomeric complex of a resolving agent and an enantiomer of interest ABIOGEN PHARMA S.P.A. (IT) 2011-06-28 US disclosed
US-20090292129-A1 PROCESS FOR RESOLVING RACEMIC MIXTURES AND A DIASTEREOISOMERIC COMPLEX OF A RESOLVING AGENT AND AN ENANTIOMER OF INTEREST ABIOGEN PHARMA S.P.A. (IT) 2009-11-26 US disclosed
EP-1986996-A2 A PROCESS FOR RESOLVING RACEMIC MIXTURES AND A DIASTEREOISOMERIC COMPLEX OF A RESOLVING AGENT AND AN ENANTIOMER OF INTEREST Abiogen Pharma S.p.A. (IT) 2008-11-05 EP disclosed
WO-2007088571-A2 A PROCESS FOR RESOLVING RACEMIC MIXTURES AND A DIASTEREOISOMERIC COMPLEX OF A RESOLVING AGENT AND AN ENANTIOMER OF INTEREST ABIOGEN PHARMA S.P.A. (IT) 2007-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090292129-A1 PROCESS FOR RESOLVING RACEMIC MIXTURES AND A DIASTEREOISOMERIC COMPLEX OF A RESOLVING AGENT AND AN ENANTIOMER OF INTEREST SRR, EPHX2, ALOX5 BLM 616/4885MEN1 2135/4885KMT2A 4634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.